Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Exopharm financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-05-10
Market Capitalization
$1.9 M
2024-05-10
CreditSafe Score
?
Score changed on Jun 12, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| AUD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 100.0K | 619.0K | ||||||
| Cost of goods sold | 45.0K | |||||||
| Gross profit | (1.0K) | 2.7M | 4.2M | 4.2M | 3.4M | 1.1M | 1.6M | |
| Gross profit margin, % | 4206.0% | 548.3% | ||||||
| Operating expense total | 173.0K | 2.3M | 7.6M | 11.7M | 12.5M | 8.5M | 6.7M | 6.7M |
| Depreciation and amortization | 1.0K | 382.0K | 1.0M | 1.7M | 1.7M | 7.0K | 193.0K | |
| EBITDA | (174.0K) | (2.3M) | (5.0M) | (7.5M) | (8.3M) | (5.1M) | (5.6M) | (5.1M) |
| EBITDA margin, % | -8278.0% | -826.3% | ||||||
| EBIT | (175.0K) | (2.3M) | (5.3M) | (8.5M) | (10.0M) | (6.8M) | (5.6M) | (5.3M) |
| EBIT margin, % | -10006.0% | -1101.3% | ||||||
| Interest income | 29.0K | 61.0K | 7.0K | 3.0K | 18.0K | 13.0K | 6.0K | |
| Interest expense | 81.0K | 331.0K | 540.0K | 8.0K | ||||
| Pre tax profit | (175.0K) | (2.3M) | (5.3M) | (8.5M) | (10.1M) | (7.1M) | (6.1M) | (5.3M) |
| Net Income | (175.0K) | (2.3M) | (5.3M) | (8.5M) | (10.1M) | (7.1M) | (6.1M) | (5.3M) |